Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals ESPP by Year
ESPP — Shares issued under Employee Stock Purchase Plan (M shares) (M)
Vertex Pharmaceuticals ESPP: 0.20M in FY2025, unchanged from a year earlier.
Latest, FY2025
0.20
Period ended Dec 31, 2025
Change on a year earlier
0.0%
0.20 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Stock-based Compensation — ESPP).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ESPP — Shares issued under Employee Stock Purchase Plan (M shares) (M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.20 | 0.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 0.20 | 0.0% | Form 10-K (filed 2025-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 0.20 | – | Form 10-K (filed 2024-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals ESPP (M), annual FY2023–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/espp-issued-sh
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.